Low expression of ORF4, a dominant negative variant of peroxisome proliferator-activated receptor γ, in colorectal adenocarcinoma

Oncology Reports

Volumn 18, Issue 2, 2007, Pages 489-495

  Bouancheau, Delphine ^a   Jarry, Anne ^a   Mottier, Stephanie ^b   Toquet, Claire ^a   Masson, Damien ^a   Mosnier, Jean François ^a   Laboisse, Christian L ^a   Denis, Marc G ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Colon cancer; Dominant negative; Expression; Peroxisome proliferator activated receptor ; Splicing variant

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; DRUG DERIVATIVE; ISOPROTEIN; MESSENGER RNA; OXAZOLE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TYROSINE;

ADENOCARCINOMA; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; CELL STRAIN CACO 2; CELL STRAIN HT29; COLORECTAL TUMOR; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; CACO-2 CELLS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; MALE; MIDDLE AGED; OXAZOLES; PPAR GAMMA; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TYROSINE;

EID: 34548536328     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.2.489     Document Type: Article

References (40)

1. Lefebvre AM, Chen I, Desreumaux P, et al: Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 4: 1053-1057, 1998. (Pubitemid 28417338)
2. Saez E, Tontonoz P, Nelson MC, et al: Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4: 1058-1061, 1998.
3. Koeffler HP: Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 9: 1-9, 2003.
4. Michalik L, Desvergne B and Wahli W: Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4: 61-70, 2004. (Pubitemid 38082154)
5. Yoshizumi T, Ohta T, Ninomiya I, et al: Thiazolidinedione, a peroxisome proliferator-activated receptor-γ ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 25: 631-639, 2004.
6. Sarraf P, Mueller E, Jones D, et al: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4: 1046-1052, 1998. (Pubitemid 28417337)
7. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S and Matsuzawa Y: Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 90: 75-80, 1999. (Pubitemid 29084314)
8. Gupta RA, Brockman JA, Sarraf P, Willson TM and Dubois RN: Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem 276: 29681-29687, 2001.
9. Osawa E, Nakajima A, Wada K, et al: Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 124: 361-367, 2003. (Pubitemid 36169253)
10. Tanaka T, Kohno H, Yoshitani S, et al: Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 61: 2424-2428, 2001. (Pubitemid 32685818)
11. Kohno H, Yoshitani S, Takashima S, et al: Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats. Jpn J Cancer Res 92: 396-403, 2001. (Pubitemid 32427775)
12. Girnun GD, Smith WM, Drori S, et al: APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA 99: 13771-13776, 2002. (Pubitemid 35215456)
13. Sarraf P, Mueller E, Smith WM, et al: Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 3: 799-804, 1999.
14. Ikezoe T, Miller CW, Kawano S, et al: Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. Cancer Res 61: 5307-5310, 2001. (Pubitemid 32681569)
15. Gupta RA, Sarraf P, Mueller E, et al: Peroxisome proliferator-activated receptor gamma-mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms. J Biol Chem 278: 22669-22677, 2003. (Pubitemid 36830326)
16. Bouancheau D, Buecher B, Jarry A, et al: The PPAR(gamma) K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment. Cancer Lett 224: 111-116, 2005. (Pubitemid 40720372)
17. Sabatino L, Casamassimi A, Peluso G, et al: A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing. J Biol Chem 280: 26517-26525, 2005. (Pubitemid 41022249)
18. Branka JE, Vallette G, Jarry A, et al: Early functional effects of Clostridium difficile toxin A on human colonocytes. Gastroenterology 112: 1887-1894, 1997. (Pubitemid 27240775)
19. Augeron C and Laboisse CL: Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate. Cancer Res 44: 3961-3969, 1984. (Pubitemid 14041623)
20. Suh N, Wang Y, Williams CR, et al: A new ligand for the peroxisome proliferator-activated receptor-gamma (PPARgamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 59: 5671-5673, 1999.
21. Blanchot-Jossic F, Jarry A, Masson D, et al: Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 207: 156-163, 2005. (Pubitemid 41404146)
22. Lefebvre M, Paulweber B, Fajas L, et al: Peroxisome proliferator- activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol 162: 331-340, 1999. (Pubitemid 29447426)
23. Perera RJ, Marcusson EG, Koo S, et al: Identification of novel PPARgamma target genes in primary human adipocytes. Gene 369: 90-99, 2006. (Pubitemid 43327335)
24. Dubuquoy L, Jansson EA, Deeb S, et al: Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 124: 1265-1276, 2003.
25. Feilchenfeldt J, Brundler MA, Soravia C, Totsch M and Meier CA: Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARgamma-coactivator 1 (PGC-1). Cancer Lett 203: 25-33, 2004. (Pubitemid 37506080)
26. Fajas L, Auboeuf D, Raspe E, et al: The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272: 18779-18789, 1997. (Pubitemid 27318225)
27. Sundvold H and Lien S: Identification of a novel peroxisome proliferator-activated receptor (PPAR) gamma promoter in man and transactivation by the nuclear receptor RORalpha1. Biochem Biophys Res Commun 287: 383-390, 2001. (Pubitemid 32917609)
28. Wang X, Southard RC and Kilgore MW: The increased expression of peroxisome proliferator-activated receptor-gamma1 in human breast cancer is mediated by selective promoter usage. Cancer Res 64: 5592-5596, 2004. (Pubitemid 39095554)
29. Fajas L, Fruchart JC and Auwerx J: PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett 438: 55-60, 1998. (Pubitemid 28517834)
30. Mukherjee R, Jow L, Croston GE and Paterniti JR Jr: Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 272: 8071-8076, 1997. (Pubitemid 27137374)
31. Ricote M, Huang J, Fajas L, et al: Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95: 7614-7619, 1998.
32. Knouff C and Auwerx J: Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 25: 899-918, 2004. (Pubitemid 39657772)
33. Elbrecht A, Chen Y, Cullinan CA, et al: Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun 224: 431-437, 1996. (Pubitemid 26268204)
34. Zhou J, Wilson KM and Medh JD: Genetic analysis of four novel peroxisome proliferator activated receptor-gamma splice variants in monkey macrophages. Biochem Biophys Res Commun 293: 274-283, 2002. (Pubitemid 34694203)
35. Chen Y, Jimenez AR and Medh JD: Identification and regulation of novel PPAR-gamma splice variants in human THP-1 macrophages. Biochim Biophys Acta 1759: 32-43, 2006.
36. Maniatis T and Tasic B: Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature 418: 236-243, 2002. (Pubitemid 34773783)
37. Cartegni L, Chew SL and Krainer AR: Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3: 285-298, 2002. (Pubitemid 34279797)
38. Venables JP: Aberrant and alternative splicing in cancer. Cancer Res 64: 7647-7654, 2004.
39. Zhu X, Daffada AA, Chan CM and Dowsett M: Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer. Int J Cancer 72: 574-580, 1997. (Pubitemid 27356155)
40. Holmila R, Fouquet C, Cadranel J, Zalcman G and Soussi T: Splice mutations in the p53 gene: case report and review of the literature. Hum Mutat 21: 101-102, 2003.